BOK Financial’s Gain Therapeutics GANX Stock Holding History

BOK Financial’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$34.6K	Buy	+20,000	New	+$36.5K	﹤0.01%	859

Other funds holding GANX

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Benedict Financial Advisors Atlanta, Georgia $504M AUM 20.67% 1-Year Est. Return

BOK Financial's GANX Position: Q3 2026 in Review

BOK Financial opened a new position in Gain Therapeutics (GANX) in Q3 2026: 20,000 shares worth $34.6K. The stake represents ﹤0.01% of the portfolio and ranks #859 among its holdings.

16 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

BOK Financial held 20,000 shares of Gain Therapeutics worth $34.6K as of Q3 2026.
Gain Therapeutics was a new BOK Financial position in Q3 2026.
Gain Therapeutics made up ﹤0.01% of BOK Financial's portfolio in Q3 2026, its #859 holding.
16 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on BOK Financial's 13F filing for Q3 2026, filed 27 Oct 2026.